- Home
- CCCC vs FIGX Comparison
CCCC vs FIGX Comparison
Compare CCCC & FIGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- FIGX
- Stock Information
- Founded
- CCCC 2015
- FIGX 2025
- Country
- CCCC United States
- FIGX United States
- Employees
- CCCC N/A
- FIGX N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- FIGX
- Sector
- CCCC Health Care
- FIGX
- Exchange
- CCCC Nasdaq
- FIGX Nasdaq
- Market Cap
- CCCC 242.3M
- FIGX 196.0M
- IPO Year
- CCCC 2020
- FIGX 2025
- Fundamental
- Price
- CCCC $2.44
- FIGX $10.08
- Analyst Decision
- CCCC Strong Buy
- FIGX
- Analyst Count
- CCCC 4
- FIGX 0
- Target Price
- CCCC $8.50
- FIGX N/A
- AVG Volume (30 Days)
- CCCC 1.5M
- FIGX 32.8K
- Earning Date
- CCCC 11-06-2025
- FIGX 01-01-0001
- Dividend Yield
- CCCC N/A
- FIGX N/A
- EPS Growth
- CCCC N/A
- FIGX N/A
- EPS
- CCCC N/A
- FIGX N/A
- Revenue
- CCCC $30,108,000.00
- FIGX N/A
- Revenue This Year
- CCCC N/A
- FIGX N/A
- Revenue Next Year
- CCCC N/A
- FIGX N/A
- P/E Ratio
- CCCC N/A
- FIGX N/A
- Revenue Growth
- CCCC N/A
- FIGX N/A
- 52 Week Low
- CCCC $1.09
- FIGX $9.95
- 52 Week High
- CCCC $5.10
- FIGX $10.15
- Technical
- Relative Strength Index (RSI)
- CCCC 49.92
- FIGX N/A
- Support Level
- CCCC $2.39
- FIGX N/A
- Resistance Level
- CCCC $2.63
- FIGX N/A
- Average True Range (ATR)
- CCCC 0.16
- FIGX 0.00
- MACD
- CCCC -0.00
- FIGX 0.00
- Stochastic Oscillator
- CCCC 57.63
- FIGX 0.00
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About FIGX FIGX Capital Acquisition Corp. Class A Ordinary Share
FIGX Capital Acquisition Corp is a blank check company.